LYCA
Lycia Therapeutics, Inc. (LYCA)
Healthcare • NASDAQ • $28.61-8.30%
- Symbol
- LYCA
- Exchange
- NASDAQ
- Sector
- Healthcare
- Industry
- Biotechnology
- Price
- $28.61
- Daily Change
- -8.30%
- Market Cap
- $1.63B
- Trailing P/E
- N/A
- Forward P/E
- N/A
- 52W High
- $36.49
- 52W Low
- $22.19
- Analyst Target
- N/A
- Dividend Yield
- 0.00%
- Beta
- N/A
Lycia Therapeutics, Inc., a biotechnology company, engages in the discovery and development of therapeutics designed to degrade disease-causing extracellular proteins for the treatment of autoimmune, inflammatory, and allergic diseases. The company develops the LYTAC platform, a modular technology designed to create therapeutics that selectively reduce the levels of pathogenic proteins. Its therapeutic candidate LCA-0061 degrades immunoglobulin E (IgE) for the treatment of allergic diseases, including food allergy. The company also develops LCA-0062, a follow-on program designed to degrade IgE for the treatment of allergic diseases. Additionally, it develops LCA-0321, a candidate designed to selectively degrade TSHR autoantibodies (thyrotropin receptor antibodies, or TRAbs), the pathogenic…
Company websiteResearch LYCA on Stk-Ai
Stk-Ai gives you screening across 100+ fundamental metrics, AI-powered analysis, target predictions, backtested signals, and portfolio tracking — all in one place.
Data shown is for informational purposes only and is not investment advice. Prices and metrics may be delayed.